Clinical Trial Update: Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity [Phase 2]

View source ↗

Summary

Phase 2 trial results for setmelanotide in rare genetic obesity disorders have been completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genetic Obesity
• Obesity
• Obesity Due to Melanocortin 4 Receptor Deficiency

Drugs mentioned

• Setmelanotide (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Genetic Obesity, Obesity | Phase 2 | Status: COMPLETED | Results posted: 2023-08-18